<DOC>
	<DOC>NCT00537771</DOC>
	<brief_summary>The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases. The second objectives are to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidences of abnormal liver function test, and time to treatment failure.</brief_summary>
	<brief_title>Liver Safety Under Upfront Arimidex vs Tamoxifen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Histologically proven HR+ invasive breast cancer Completed all primary surgery and chemotherapy (if given), and were candidates to receive hormonal adjuvant therapy Postmenopausal woman clinical evidence of metastatic disease previous adjuvant hormonal therapy for breast cancer liver diseases</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Early Breast cancer</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>hormone receptor</keyword>
	<keyword>hormonal therapy</keyword>
	<keyword>anastrozole</keyword>
	<keyword>tamoxifen</keyword>
</DOC>